(MENAFN- GlobeNewsWire - Nasdaq) The Global MRD Testing Market is expanding due to rising cancer and hematological malignancy rates and advances in diagnostic tech like next-gen sequencing. Challenges include high costs limiting access. A trend is the adoption of MRD testing for solid tumors, with firms like Illumina investing in new assays.

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease (MRD) Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets's offering.
The Global Minimal Residual Disease (MRD) Testing Market, valued at USD 1.45 Billion in 2024, is projected to experience a CAGR of 8.70% to reach USD 2.39 Billion by 2030.

Minimal residual disease (MRD) testing identifies minute quantities of cancer cells remaining in a patient's body post-treatment, often undetectable by conventional methods, which significantly predict disease relapse. This global market's expansion is fundamentally driven by the rising incidence of various hematological malignancies and continuous advancements in diagnostic technologies, such as next-generation sequencing and highly sensitive flow cytometry.

The escalating global incidence of cancer and hematological malignancies represents a primary force propelling the minimal residual disease testing market. As the population grows and ages, the number of new cancer diagnoses continues to rise, directly increasing the patient pool requiring sophisticated monitoring tools throughout their treatment journey and follow-up. MRD testing becomes crucial in managing these conditions by offering precise detection of residual disease after therapy, guiding subsequent treatment decisions, and identifying patients at high risk of relapse.
The high cost associated with advanced minimal residual disease testing technologies represents a significant impediment to market expansion. These economic considerations directly limit patient access and hinder widespread adoption, especially in healthcare systems facing budget constraints or where high patient out-of-pocket expenses are prevalent. The advanced methodologies and specialized infrastructure required for these tests contribute to their elevated cost, thereby making them less attainable for a wider patient demographic.
The expanding clinical utility of minimal residual disease (MRD) testing in solid tumors represents a significant market trend, moving beyond its established role in hematological malignancies. This shift is driven by the clear need for more precise post-treatment monitoring and recurrence prediction in a broader patient population. According to the American Cancer Society, in 2023, an estimated 1,958,310 new cancer cases were projected to occur in the United States, with solid tumors constituting the vast majority of these diagnoses, highlighting a substantial and underserved patient base for advanced monitoring solutions.

This expansion is further underscored by industry developments, such as Illumina Inc. 's announcement in January 2024 of a collaboration with Janssen Research & Development, LLC to develop a novel molecular residual disease assay. This whole-genome sequencing multi-cancer research solution is specifically designed to detect circulating tumor DNA for various solid tumor indications, signaling growing investment and technological application in this area.

Key Attributes:

Report Attribute	Details
No. of Pages	185
Forecast Period	2024 - 2030
Estimated Market Value (USD) in 2024	$1.45 Billion
Forecasted Market Value (USD) by 2030	$2.39 Billion
Compound Annual Growth Rate	8.7%
Regions Covered	Global

Report Scope:

Key Market Players Profiled:

• ICON plc
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Laboratory Corporation of America Holdings
• Natera, Inc.
• Cergentis B.V.
• OPKO Health, Inc.
• Sysmex Corporation
• Mission Bio, Inc.
• Invivoscribe, Inc.

By Technology:

• Flow Cytometry
• Polymerase Chain Reaction
• Next Generation Sequencing
• Others

By Application:

• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

By End User:

• Hospitals & Specialty Clinics
• Academic & Research Institutions
• Clinical Laboratories
• Others

By Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Minimal Residual Disease (MRD) Testing Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01122025004107003653ID1110419765